A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25
(zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2
(HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including
intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and
gallbladder cancer (GBC).